/C O R R E C T I O N -- BioLife Solutions, Inc./

PR Newswire

In the news release, BioLife Solutions Announces Participation and Additional Product Citations at 19th ISCT Annual Meeting, issued 06-May-2013 by BioLife Solutions, Inc. over PR Newswire, we are advised by the company that the meeting date in the first paragraph should read "April 22 - 25" rather than "June 22 - 25." The complete, corrected release follows:

BioLife Solutions Announces Participation and Additional Product Citations at 19th ISCT Annual Meeting

Continued Adoption of CryoStor® and HypoThermosol® in Clinical Applications

BOTHELL, Wash., May 6, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today provided an overview of the Company's participation at the 19th Annual Meeting of the International Society for Cellular Therapy, which was held from April 22 – 25, in Auckland, New Zealand.

Dr. Aby J. Mathew, Ph.D., Senior Vice President and Chief Technology Officer, represented industry on a panel session titled Cells from banked tissue – novel applications, regulatory considerations and questions.  Dr. Mathew also presented a corporate tutorial titled Roadmap for Cell/Tissue Stability Gap Analysis and Clinical Qualification of Biopreservation Excipients/Ancillary Reagents.

BioLife products were also cited in the following poster presentations:

  • Analysis of HPC and HSC Post-Thaw Viability, Clonogenic Capacity, and Proliferative Potential After Cryopreservation in Commercially Available Media; Hoxworth Blood Center, Cincinnati, OH USA; it may be advantageous to use the commercially available media for cryopreservation and storage of HPC products intended for transplant.
  • Development and Validation of a Fully GMP-Compliant Production Process of Autologous, Tumor-Lysate Pulsed Dendritic Cells; Children's Hospital, Wuerzburg, Germany; vitality and functionality of thawed DCs (following cryopreservation in CryoStor CS5) were extensively validated and showed no significant loss of function.

Several oral presentations and posters highlighted sub-optimal stability and other issues with cryopreserved and non-frozen therapeutic products, continuing to expose the need for process improvements, which could potentially be enabled through the use of BioLife's HypoThermosol and CryoStor platform technologies.

Mike Rice, Chief Executive Officer, commented on BioLife's presence at the conference by stating, "The regenerative medicine industry, comprised of commercial and non-profit organizations developing or already providing cellular therapies and tissue-engineered products is our most strategic market.  At this year's ISCT annual meeting, we continued to see increased adoption of our best-in-class, clinical grade cell and tissue storage and freeze media products, as the critical impact of biopreservation outcomes on commercial viability of new biologic-based approaches is recognized as a key area of process improvement."

BioLife Solutions devoted its Spring 2013 issue of BioPreservation Today to the state of the regenerative medicine market in Australia, along with an overview of the worldwide market, contributed by the Alliance for Regenerative Medicine.  This issue can be found here: Spring 2013 BioPreservation Today.

Rice continued, "A key differentiator we provide our customers is expert consulting in optimizing biopreservation processes to improve outcomes.  Our expertise is increasingly being recognized through invitations for Dr. Mathew and others on our team to present at relevant conferences to serve as scientific and educational resources for industry."

About BioLife Solutions

BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. 

Media Relations:

Investor Relations:


Len Hall

Matt Clawson


Allen & Caron Inc

Allen & Caron Inc


(949) 474-4300

(949) 474-4300


len@allencaron.com

matt@allencaron.com





 

 

 

View Comments